UroGen Pharma Ltd.

URGN

$28.18

Name : UroGen Pharma Ltd.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,372,977,536.00

EPSttm : -2.74

UroGen Pharma Ltd.

$28.18

3.41%

$0.93

URGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.57

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

0.36

EPS Last/This Y

2.29

EPS This/Next Y

2.13

Price

28.15

Target Price

36.88

Analyst Recom

1.25

Performance Q

44.88

Upside

-441.6%

Beta

1.63

Ticker: URGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-05-11	URGN	31.28	0.66	0.10	9324
2026-05-12	URGN	29.8	0.64	0.11	9481
2026-05-13	URGN	30.96	0.62	0.10	9813
2026-05-14	URGN	29.67	0.62	0.38	9804
2026-05-15	URGN	28.77	0.61	1.01	9916
2026-05-18	URGN	28.6	0.53	0.32	6953
2026-05-19	URGN	28.24	0.54	0.22	7202
2026-05-20	URGN	30.2	0.53	1.32	7286
2026-05-21	URGN	29.89	0.54	0.13	7323
2026-05-22	URGN	28.86	0.52	0.00	7453
2026-05-26	URGN	29.4	0.52	0.01	7462
2026-05-27	URGN	29.32	0.52	0.00	7488
2026-05-28	URGN	28.73	0.52	0.59	7492
2026-05-29	URGN	28.12	0.52	1.25	7519
2026-06-02	URGN	26.58	0.53	2.63	7497
2026-06-03	URGN	26.6	0.52	0.40	7452
2026-06-04	URGN	27.54	0.52	1.20	7448
2026-06-05	URGN	26.79	0.52	0.00	7482
2026-06-08	URGN	27.31	0.52	0.03	7496
2026-06-09	URGN	28.2	0.51	0.06	7649
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-05-11	URGN	31.28	65.7	-	-0.89
2026-05-12	URGN	29.80	71.1	-	-0.89
2026-05-13	URGN	30.93	71.1	-	-0.89
2026-05-14	URGN	29.67	71.1	-	-0.83
2026-05-15	URGN	28.78	71.1	-	-0.83
2026-05-18	URGN	28.61	77.3	-	-0.89
2026-05-19	URGN	28.27	77.3	-	-0.89
2026-05-20	URGN	30.25	72.7	-	-0.89
2026-05-21	URGN	29.87	72.7	-	-0.89
2026-05-22	URGN	28.87	72.7	-	-0.89
2026-05-26	URGN	29.42	72.7	-	-0.89
2026-05-27	URGN	29.30	72.7	-	-0.89
2026-05-28	URGN	28.74	72.7	-	-0.89
2026-05-29	URGN	28.12	72.7	-	-0.89
2026-06-01	URGN	27.08	71.1	-	-0.91
2026-06-02	URGN	26.57	71.1	-	-0.91
2026-06-03	URGN	26.60	71.1	-	-0.91
2026-06-04	URGN	27.61	71.1	-	-0.91
2026-06-05	URGN	26.84	71.1	-	-0.91
2026-06-08	URGN	27.25	71.1	-	-0.91
2026-06-09	URGN	28.15	71.1	-	-0.91
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-05-11	URGN	-0.34	3.73	20.30
2026-05-12	URGN	-0.34	3.73	18.77
2026-05-13	URGN	-0.34	3.73	18.77
2026-05-14	URGN	-0.34	3.73	18.77
2026-05-15	URGN	-0.34	3.73	18.77
2026-05-18	URGN	-0.34	3.86	18.76
2026-05-19	URGN	-0.34	3.86	18.76
2026-05-20	URGN	-0.34	3.86	18.76
2026-05-21	URGN	-0.24	3.86	18.76
2026-05-22	URGN	-0.24	3.86	18.76
2026-05-26	URGN	-0.24	1.01	18.82
2026-05-27	URGN	-0.24	1.01	18.82
2026-05-28	URGN	-0.24	1.01	17.59
2026-05-29	URGN	-0.24	1.01	17.59
2026-06-02	URGN	-0.24	0.98	17.59
2026-06-03	URGN	-0.24	0.98	17.59
2026-06-04	URGN	-0.24	0.98	17.57
2026-06-05	URGN	-0.24	0.98	17.57
2026-06-08	URGN	-0.24	0.98	17.57
2026-06-09	URGN	-0.29	0.98	17.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.47

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

-0.29

Institutional Transactions

0.98

Beta

1.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-82.6

Target Price

36.88

P/E

Forward P/E

22.93

PEG

P/S

9.77

P/B

P/Free Cash Flow

EPS

-2.75

Average EPS Est. Cur. Y

-0.91

EPS Next Y. (Est.)

1.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-94.83

Relative Volume

1.03

Return on Equity vs Sector %

79.7

Return on Equity vs Industry %

95.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.18

EBIT Estimation

◆ URGN Healthcare

$28.18

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

18/20

Pullback

14/25

Volume

4/15

Valuation

10/20

TP/AR

2/10

Options

7/10

RSI

Range 1M

29.5%

Sup Dist

5.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

12/25

Growth

26/30

Estimates

1/20

Inst/Vol

8/15

Options

7/10

EPS Yr

71.6%

EPS NY

235.9%

52W%

82.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +46.5% upside

Quality

7/30

Valuation

12/30

Growth

18/25

Stability

8/10

LT Trend

4/5

Upside

+46.5%

Quality

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 298

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

URGN

Latest News

—

Caricamento notizie per URGN…

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y